Announced via Bloomberg, Congresswoman Rosa DeLauro wrote to FDA Commissioner Robert Califf on Tuesday, March 7th, questioning whether the agency plans to investigate GSK’s actions regarding Zantac. Earlier this year, Bloomberg Businessweek covered how Zantac and its generics were removed from the market in April 2020 after Valisure identified NDMA in ranitidine in 2019. Lawyers have debated the methodologies in recent lawsuits, but the core problem of ranitidine degrading into NDMA has since been confirmed by manufacturer tests and recalls, FDA’s analyses, and even Zantac’s developer, GlaxoSmithKline’s scientists in 2020, and recently unveiled reports from 1982, as shown by Bloomberg’s February article. DeLauro’s letter asked how the FDA plans to investigate the new findings and hold the company accountable.

Announced via Bloomberg, Congresswoman Rosa DeLauro wrote to FDA Commissioner Robert Califf on Tuesday, March 7th, questioning whether the agency plans to investigate GSK’s actions regarding Zantac. Earlier this year, Bloomberg Businessweek covered how Zantac and its generics were removed from the market in April 2020 after Valisure identified NDMA in ranitidine in 2019. Lawyers have debated the methodologies in recent lawsuits, but the core problem of ranitidine degrading into NDMA has since been confirmed by manufacturer tests and recalls, FDA’s analyses, and even Zantac’s developer, GlaxoSmithKline’s scientists in 2020, and recently unveiled reports from 1982, as shown by Bloomberg’s February article. DeLauro’s letter asked how the FDA plans to investigate the new findings and hold the company accountable.